Therapeutic Applications of Nicotinic Stimulation: Successes, Failures, and Future Prospects

Overview

Journal Nicotine Tob Res

Publisher Oxford University Press

Specialty Public Health

Date 2018 Sep 12

PMID 30203054

Citations 5

Authors

Paul A Newhouse

Affiliations

Soon will be listed here.

Citing Articles

Challenges in legitimizing further measures against smoking in jurisdictions with robust infrastructure for tobacco control: how far can the authorities allow themselves to go?.

Lund K, Saebo G Harm Reduct J. 2024; 21(1):33.

PMID: 38321438 PMC: 10848560. DOI: 10.1186/s12954-024-00951-w.

Nicotine-mediated effects in neuronal and mouse models of synucleinopathy.

Fares M, Alijevic O, Johne S, Overk C, Hashimoto M, Kondylis A Front Neurosci. 2023; 17:1239009.

PMID: 37719154 PMC: 10501483. DOI: 10.3389/fnins.2023.1239009.

The Basal Forebrain Cholinergic Nuclei and Their Relevance to Schizophrenia and Other Psychotic Disorders.

Eickhoff S, Franzen L, Korda A, Rogg H, Trulley V, Borgwardt S Front Psychiatry. 2022; 13:909961.

PMID: 35873225 PMC: 9299093. DOI: 10.3389/fpsyt.2022.909961.

Bio-oils from vacuum ablative pyrolysis of torrefied tobacco residues.

Khuenkaeo N, MacQueen B, Onsree T, Daiya S, Tippayawong N, Lauterbach J RSC Adv. 2022; 10(58):34986-34995.

PMID: 35515664 PMC: 9056820. DOI: 10.1039/d0ra06014c.

Healthy Subjects With Extreme Patterns of Performance Differ in Functional Network Topology and Benefits From Nicotine.

Giessing C, Ahrens S, Thiel C Front Syst Neurosci. 2020; 13:83.

PMID: 31998085 PMC: 6965056. DOI: 10.3389/fnsys.2019.00083.

References

Gratton C, Yousef S, Aarts E, Wallace D, DEsposito M, Silver M . Cholinergic, But Not Dopaminergic or Noradrenergic, Enhancement Sharpens Visual Spatial Perception in Humans. J Neurosci. 2017; 37(16):4405-4415. PMC: 5413181. DOI: 10.1523/JNEUROSCI.2405-16.2017. View

Levin E, McClernon F, Rezvani A . Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl). 2005; 184(3-4):523-39. DOI: 10.1007/s00213-005-0164-7. View

Terry A, Callahan P . Nicotinic Acetylcholine Receptor Ligands, Cognitive Function, and Preclinical Approaches to Drug Discovery. Nicotine Tob Res. 2018; 21(3):383-394. PMC: 6379039. DOI: 10.1093/ntr/nty166. View

Sultzer D, Melrose R, Riskin-Jones H, Narvaez T, Veliz J, Ando T . Cholinergic Receptor Binding in Alzheimer Disease and Healthy Aging: Assessment In Vivo with Positron Emission Tomography Imaging. Am J Geriatr Psychiatry. 2017; 25(4):342-353. DOI: 10.1016/j.jagp.2016.11.011. View

Prickaerts J, van Goethem N, Chesworth R, Shapiro G, Boess F, Methfessel C . EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology. 2011; 62(2):1099-110. DOI: 10.1016/j.neuropharm.2011.10.024. View

Gotti C, Fornasari D, Clementi F . Human neuronal nicotinic receptors. Prog Neurobiol. 1997; 53(2):199-237. DOI: 10.1016/s0301-0082(97)00034-8. View

Keefe R, Meltzer H, Dgetluck N, Gawryl M, Koenig G, Moebius H . Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia. Neuropsychopharmacology. 2015; 40(13):3053-60. PMC: 4864641. DOI: 10.1038/npp.2015.176. View

Kamkwalala A, Newhouse P . Beyond Acetylcholinesterase Inhibitors: Novel Cholinergic Treatments for Alzheimer's Disease. Curr Alzheimer Res. 2016; 14(4):377-392. DOI: 10.2174/1567205013666160930112625. View

Potter A, Corwin J, LANG J, Piasecki M, Lenox R, Newhouse P . Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology (Berl). 1999; 142(4):334-42. DOI: 10.1007/s002130050897. View

10.

Dunbar G, Boeijinga P, Demazieres A, Cisterni C, Kuchibhatla R, Wesnes K . Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berl). 2007; 191(4):919-29. DOI: 10.1007/s00213-006-0675-x. View

11.

Dunbar G, Kuchibhatla R, Lee G . A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment. J Psychopharmacol. 2010; 25(8):1020-9. DOI: 10.1177/0269881110367727. View

12.

Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol J . A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Mov Disord. 2016; 31(7):1049-54. DOI: 10.1002/mds.26569. View

13.

Kendziorra K, Wolf H, Meyer P, Barthel H, Hesse S, Becker G . Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging. 2010; 38(3):515-25. DOI: 10.1007/s00259-010-1644-5. View

14.

Tregellas J, Tanabe J, Rojas D, Shatti S, Olincy A, Johnson L . Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry. 2010; 69(1):7-11. PMC: 3005969. DOI: 10.1016/j.biopsych.2010.07.004. View

15.

Satlin A, Wang J, Logovinsky V, Berry S, Swanson C, Dhadda S . Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease. Alzheimers Dement (N Y). 2017; 2(1):1-12. PMC: 5644271. DOI: 10.1016/j.trci.2016.01.001. View

16.

Wesnes K, Warburton D . Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology (Berl). 1984; 82(3):147-50. DOI: 10.1007/BF00427761. View

17.

Gandelman J, Kang H, Antal A, Albert K, Boyd B, Conley A . Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Nonsmokers With Late-Life Depression. J Clin Psychiatry. 2018; 79(5). PMC: 6129985. DOI: 10.4088/JCP.18m12137. View

18.

Frolich L, Ashwood T, Nilsson J, Eckerwall G . Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study. J Alzheimers Dis. 2011; 24(2):363-74. DOI: 10.3233/JAD-2011-101554. View

19.

Moll H . The Treatment of Post-Encephalitig Parkinsonism by Nicotine. Br Med J. 2010; 1(3416):1079-81. PMC: 2524155. DOI: 10.1136/bmj.1.3416.1079. View

20.

Potter A, Newhouse P, Bucci D . Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder?. Behav Brain Res. 2006; 175(2):201-11. DOI: 10.1016/j.bbr.2006.09.015. View